|
NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets
|
LianBio to collaborate in the development of NBTXR3, and contribute to enrollment in five future global registrational studies across several tumor types and therapeutic combinations including immunotherapy Supports the expansion of global phase II...
Full "IntellAsia: Resources" article
|
|